A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat
Completed
Pfizer
Phase 3
2003-02-01
The study was performed to evaluate the analgesic efficacy, safety, and tolerability of
valdecoxib 20 mg twice daily (BID), valdecoxib 40 mg once daily (QD), and placebo in patients
with moderately to severely painful symptomatic sore throat over a 24-hour period. In
addition, the study was to validate a new scale and criteria for measuring pain in sore
throat and evaluate the effects of selective serotonin reuptake inhibitors and past sore
throat pain on pain score and efficacy of analgesics. The study also examined what type of
medications are commonly used for sore throat and whether this information has relevance to
analgesic efficacy.
Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
Completed
Pfizer
Phase 4
2003-02-01
The objectives of the study were to evaluate the efficacy, safety, and tolerability of
valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to
assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs
and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.
A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain
Terminated
Pfizer
Phase 4
2004-06-01
The objectives of this study were to assess the analgesic efficacy and safety of
parecoxib/valdecoxib on post-laparoscopic surgery analgesia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
